Company / SG&A Expense
Neogen SG&A Expense History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$218.2M
FY2024
5-year range
$82.7M / $218.2M
FY2020-FY2024
Trend
+9.1%
vs FY2023
Sector context
#100 of 152
Health Care
What the data says
At $218M, Neogen's sg&a expense ranks #53 of 152 in the Health Care sector. Increased from $201M to $218M over the past 2 years.
Based on SEC 10-K filings.
$218M in FY2024 with a 5-year CAGR of +37.5%.
Increased from $201M to $218M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +38.2%
- 5-Year CAGR
- +37.5%
- 10-Year CAGR
- -
Sector benchmark
#53 of 152 in Health CareTop 34% of 152This company $218.2M Sector average $182.7B
▼
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +37.5%, indicating consistent growth.
- In FY2024, sg&a expense increased 9.1% year-over-year.
- Ranks #100 out of 152 companies in the Health Care sector.
- Lowest sg&a expense in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.59 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $218.2M | +9.1% |
| FY2023 | $199.9M | -0.6% |
| FY2022 | $201.2M | +143.1% |
| FY2021 | $82.7M | +61.6% |
| FY2020 | $51.2M | +15.5% |
| FY2019 | $44.3M | +8.7% |
| FY2018 | $40.8M | +6.5% |
| FY2017 | $38.3M | +11.9% |
| FY2016 | $34.2M | +17.2% |
As of FY2024 · SEC 10-K · Updated Mar 28, 2026